| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Bictegravir/emtricitabine/tenofovir alafenamide |
| Brand | Biktarvy® |
| Indication | Treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components. |
| Assessment Process | |
| Rapid review commissioned | 30/04/2018 |
| Rapid review completed | 07/06/2018 |
| Rapid review outcome | Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013. |
The HSE has approved reimbursement following confidential price negotiations December 2018.
